All In Biotech

Drug Trial Radar · NCT00546650

Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®

A Phase I, Single Center, Open Label, Randomized, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Nov 2007

Primary completion

Dec 2007

Study completion Mar 2008

Sponsor

Lead sponsor
NuPathe Inc.Industry
Sponsor type
Industry
First posted
Oct 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to compare the pharmacokinetics (PK) of NP101 with the currently approved oral, injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.

Conditions

  • Healthy

Interventions

  • Sumatriptan succinateDrug

    NP101 iontophoretic transdermal system

  • Sumatriptan succinateDrug

    oral, subcutaneous, and intranasal formulations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PharmacokineticsTime frame: Blood samples to be drawn at pre-dose (within 15 minutes prior to dosing) and at 0.25, 0.50, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 16 hrs post dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Orlando Clinical Research Center

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.